If you are still having problems viewing this message, please click here for additional help.


See how droplets are guiding precision medicine 

Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring. Is your lab using this tool to its full potential? See how a promising new technology lets you give clinicians insights that can guide personalized cancer treatments.

Volume 32, Issue 7

In this issue
Review Article
Also new
Now Enrolling - Clinical studies for oral pracinostat in Acute Myeloid Leukemia (AML) Patients Unfit for Induction Chemotherapy and in Myelodysplastic Syndromes (MDS) trials

Pracinostat is an investigational agent not approved for commercial use by the FDA or any other regulatory agency worldwide



New drugs in AML: uses and abuses

Elihu H. Estey, Robert Peter Gale & Mikkael A. Sekeres

Leukemia 2018 32 :1479 - 1481; June 06, 2018; 10.1038/s41375-018-0168-z


Abstract | Full Text


Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?

Kiran Tawana, Michael W. Drazer & Jane E. Churpek

Leukemia 2018 32 :1482 - 1492; February 27, 2018; 10.1038/s41375-018-0051-y


Abstract | Full Text

Review Article

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion

Alan List, Benjamin L. Ebert & Pierre Fenaux

Leukemia 2018 32 :1493 - 1499; January 30, 2018; 10.1038/s41375-018-0029-9


Abstract | Full Text

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

Song Xu, Kim De Veirman, Ann De Becker, Karin Vanderkerken & Ivan Van Riet

Leukemia 2018 32 :1500 - 1514; February 22, 2018; 10.1038/s41375-018-0061-9


Abstract | Full Text

Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis

Maria Maruffi, Richard Sposto, Matthew J Oberley, Lynn Kysh & Etan Orgel

Leukemia 2018 32 :1515 - 1528; February 27, 2018; 10.1038/s41375-018-0058-4


Abstract | Full Text

Clinical use of lentiviral vectors

Michael C. Milone & Una O’Doherty

Leukemia 2018 32 :1529 - 1541; March 22, 2018; 10.1038/s41375-018-0106-0


Abstract | Full Text

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Heinz Ludwig, Michel Delforge, Thierry Facon, Hermann Einsele, Francesca Gay et al.

Leukemia 2018 32 :1542 - 1560; May 02, 2018; 10.1038/s41375-018-0040-1


Abstract | Full Text


Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

Charlotte Pawlyn, Andrea Loehr, Cody Ashby, Ruslana Tytarenko, Shayu Deshpande et al.

Leukemia 2018 32 :1561 - 1566; February 02, 2018; 10.1038/s41375-018-0017-0


Abstract | Full Text

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Amrita Krishnan, Prashant Kapoor, Joycelynne M. Palmer, Ni-Chun Tsai, Shaji Kumar et al.

Leukemia 2018 32 :1567 - 1574; February 23, 2018; 10.1038/s41375-018-0038-8


Abstract | Full Text

A human bone marrow mesodermal-derived cell population with hemogenic potential

Saloomeh Mokhtari, Evan Colletti, Weihong Yin, Chad Sanada, Zanetta Lamar et al.

Leukemia 2018 32 :1575 - 1586; February 02, 2018; 10.1038/s41375-018-0016-1


Abstract | Full Text

ANP32A regulates histone H3 acetylation and promotes leukemogenesis

Xuejing Yang, Bin Lu, Xueqin Sun, Cuijuan Han, Chunling Fu et al.

Leukemia 2018 32 :1587 - 1597; February 02, 2018; 10.1038/s41375-018-0010-7


Abstract | Full Text

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

Maja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, Thomas Köhnke, Nikola P. Konstandin et al.

Leukemia 2018 32 :1598 - 1608; February 23, 2018; 10.1038/s41375-018-0034-z


Abstract | Full Text

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

Maria Chiara Fontana, Giovanni Marconi, Jelena D. Milosevic Feenstra, Eugenio Fonzi, Cristina Papayannidis et al.

Leukemia 2018 32 :1609 - 1620; February 23, 2018; 10.1038/s41375-018-0035-y


Abstract | Full Text

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

Peter Paschka, Richard F Schlenk, Daniela Weber, Axel Benner, Lars Bullinger et al.

Leukemia 2018 32 :1621 - 1630; April 17, 2018; 10.1038/s41375-018-0129-6


Abstract | Full Text

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy et al.

Leukemia 2018 32 :1631 - 1642; March 23, 2018; 10.1038/s41375-018-0107-z


Abstract | Full Text

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

Oscar Brück, Sami Blom, Olli Dufva, Riku Turkki, Himanshu Chheda et al.

Leukemia 2018 32 :1643 - 1656; June 20, 2018; 10.1038/s41375-018-0175-0


Abstract | Full Text

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial

Meinolf Suttorp, Philipp Schulze, Ingmar Glauche, Gudrun Göhring, Nils von Neuhoff et al.

Leukemia 2018 32 :1657 - 1669; June 20, 2018; 10.1038/s41375-018-0179-9


Abstract | Full Text


Correction: A human bone marrow mesodermal-derived cell population with hemogenic potential

Saloomeh Mokhtari, Evan Colletti, Weihong Yin, Chad Sanada, Zanetta Lamar et al.

Leukemia 2018 32 :1670 - 1670; June 11, 2018; 10.1038/s41375-018-0172-3


Abstract | Full Text

Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature